SLC5A2 and Hypoglycemia: The advent of newer classes of agents (e.g., SGLT2-inhibitors and GLP-1 agonists) that have proven cardiorenal benefits [36,37] and less risk of hypoglycemia may offer safer CVD risk reduction, if they can be accessed broadly [38].